

Napa Parinyanitikul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8953108/publications.pdf>

Version: 2024-02-01

26
papers

208
citations

1307594

7
h-index

1058476

14
g-index

26
all docs

26
docs citations

26
times ranked

569
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 745-753. | 2.5 | 46 |
| 2 | Functional consequence of the MET 1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614. | 1.8 | 34 |
| 3 | Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. <i>Clinical Breast Cancer</i> , 2015, 15, 153-160. | 2.4 | 33 |
| 4 | Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 378-384. | 2.4 | 32 |
| 5 | Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. <i>PeerJ</i> , 2019, 7, e6501. | 2.0 | 18 |
| 6 | Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. <i>Supportive Care in Cancer</i> , 2018, 26, 2471-2477. | 2.2 | 12 |
| 7 | Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412. | 4.1 | 9 |
| 8 | Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. <i>JCO Precision Oncology</i> , 2022, 6, e2000368. | 3.0 | 9 |
| 9 | Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. <i>Cancer Reports</i> , 2022, 5, e1575. | 1.4 | 5 |
| 10 | Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration. <i>Asian Biomedicine</i> , 2017, 10, 371-377. | 0.3 | 3 |
| 11 | Prevalence of KRAS gene mutation in ampullary cancer in Thai patients. <i>Journal of Clinical Oncology</i> , 2014, 32, e15175-e15175. | 1.6 | 2 |
| 12 | Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. <i>Journal of Breast Cancer</i> , 0, 25, . | 1.9 | 2 |
| 13 | Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098546. | 3.2 | 1 |
| 14 | Feasibility of withholding dexamethasone premedication in patients not experiencing two previous cycles of weekly paclitaxel related infusion hypersensitivity reaction. <i>Journal of Clinical Oncology</i> , 2016, 34, e21634-e21634. | 1.6 | 1 |
| 15 | What is the best systemic treatment for newly diagnosed inflammatory breast cancer?—a narrative review. <i>Chinese Clinical Oncology</i> , 2021, 10, 55-55. | 1.2 | 1 |
| 16 | Analysis of KRT14 and SFTPB expression by immunohistochemistry method in squamous cell carcinoma of lung and head-neck cancer tissue. <i>Journal of Clinical Oncology</i> , 2014, 32, e22127-e22127. | 1.6 | 0 |
| 17 | Effect of adjuvant trastuzumab (T) among patients treated with neoadjuvant T-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 644-644. | 1.6 | 0 |
| 18 | The cost-effectiveness analysis of EGFR mutation test for management of advanced non-small cell lung cancer in Thailand. <i>Journal of Clinical Oncology</i> , 2016, 34, e20636-e20636. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The accuracy of carboplatin area under the curve (AUC) estimated by Calvert formula using Cockcroft-Gault formula and Thai eGFR in Thai cancer patients.. Journal of Clinical Oncology, 2016, 34, e14017-e14017. | 1.6 | 0 |
| 20 | A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2018, 36, 467-467. | 1.6 | 0 |
| 21 | Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs).. Journal of Clinical Oncology, 2018, 36, 12069-12069. | 1.6 | 0 |
| 22 | Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.. Journal of Clinical Oncology, 2018, 36, 10019-10019. | 1.6 | 0 |
| 23 | Prognostic significance of cyclin B1 expression plus clinicopathologic features in hormonal positive, HER2 negative early breast cancer in King Chulalongkorn Memorial Hospital During 2010-2015.. Journal of Global Oncology, 2019, 5, 75-75. | 0.5 | 0 |
| 24 | Rate of complete chemotherapy as planned with comprehensive geriatric assessment guided intervention among vulnerable elderly cancer patients: A randomized-open-label study.. Journal of Clinical Oncology, 2020, 38, e24021-e24021. | 1.6 | 0 |
| 25 | An open-label, randomized, controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.. Journal of Clinical Oncology, 2022, 40, 12099-12099. | 1.6 | 0 |
| 26 | Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557. | 1.6 | 0 |